Jinhui Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinhui Xue has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Hongyun Zhao
Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
32 shared publications - Li Zhang
Sun Yat-sen University Cancer Center
32 shared publications - Yuanyuan Zhao
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China
31 shared publications - Shaodong Hong
State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
30 shared publications - Wenfeng Fang
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
30 shared publications - Yan Huang
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
30 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Elsevier in JTO Clinical and Research Reports
Antibody-Drug Conjugate Combined with Immunotherapy in SMARCA4-Deficient Non-Small Cell Lung Cancer: A Case Series
- 13 November 2026
- Published by Elsevier in JTO Clinical and Research Reports
Open AccessAntibody-Drug Conjugate Combined with Immunotherapy in SMARCA4-Deficient Non-Small Cell Lung Cancer: A Case Series
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Table S4 shows that list of genes included in the SYSUCC Personalized Diagnostics Panel (Tumor tissues).
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Table S4 shows that list of genes included in the SYSUCC Personalized Diagnostics Panel (Tumor tissues).
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Table S1 shows that the transcription of fusion genes were detected by whole transcriptome sequencing (WTS) in patient #1's specimen.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Table S1 shows that the transcription of fusion genes were detected by whole transcriptome sequencing (WTS) in patient #1's specimen.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Although epidermal growth factor receptor (EGFR) fusions in non–small cell lung cancer (NSCLC) typically show sensitivity to tyrosine kinase inhibitors (TKI), we identified an EGFR–SHC1 fusion subtype that exhibits intrinsic resistance to EGFR-TKI monotherapy through a dual-activation mechanism in the preclinical and clinical settings. EGFR–SHC1 fusion protein comprises of N-terminal EGFR and C-terminal SHC1. We demonstrated that EGFR–SHC1 simultaneously activates the EGFR kinase domain (KD) and SRC-mediated phosphorylation of the SHC1 fusion partner, thereby driving ERK/AKT pathway activation and tumorigenesis independent of KD inhibition. Structural modeling coupled with domain-specific mutagenesis revealed that SHC1 phosphorylation establishes a kinase-independent bypass mechanism. Notably, dual-targeted inhibition using afatinib (EGFR-TKI) in combination with dasatinib (SRC-TKI) induced marked tumor regression in a TKI-refractory patient with NSCLC with EGFR–SHC1. This study illustrates a cooperative oncogenesis between kinases and scaffold proteins in fusions, providing a clinically actionable strategy for overcoming TKI resistance in patients with these oncogenic fusions. Significance:This study identifies a previously unrecognized mode of oncogenic signaling in receptor tyrosine kinase (RTK) fusions, in which a non-kinase fusion partner actively drives tumorigenesis through kinase-independent mechanisms. By challenging the classical kinase-centric model of RTK fusions, it provides a framework for understanding intrinsic resistance to TKIs and for developing rational combination therapies.See related commentary by Le and Wolf, p. 1480
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Although epidermal growth factor receptor (EGFR) fusions in non–small cell lung cancer (NSCLC) typically show sensitivity to tyrosine kinase inhibitors (TKI), we identified an EGFR–SHC1 fusion subtype that exhibits intrinsic resistance to EGFR-TKI monotherapy through a dual-activation mechanism in the preclinical and clinical settings. EGFR–SHC1 fusion protein comprises of N-terminal EGFR and C-terminal SHC1. We demonstrated that EGFR–SHC1 simultaneously activates the EGFR kinase domain (KD) and SRC-mediated phosphorylation of the SHC1 fusion partner, thereby driving ERK/AKT pathway activation and tumorigenesis independent of KD inhibition. Structural modeling coupled with domain-specific mutagenesis revealed that SHC1 phosphorylation establishes a kinase-independent bypass mechanism. Notably, dual-targeted inhibition using afatinib (EGFR-TKI) in combination with dasatinib (SRC-TKI) induced marked tumor regression in a TKI-refractory patient with NSCLC with EGFR–SHC1. This study illustrates a cooperative oncogenesis between kinases and scaffold proteins in fusions, providing a clinically actionable strategy for overcoming TKI resistance in patients with these oncogenic fusions. Significance:This study identifies a previously unrecognized mode of oncogenic signaling in receptor tyrosine kinase (RTK) fusions, in which a non-kinase fusion partner actively drives tumorigenesis through kinase-independent mechanisms. By challenging the classical kinase-centric model of RTK fusions, it provides a framework for understanding intrinsic resistance to TKIs and for developing rational combination therapies.See related commentary by Le and Wolf, p. 1480
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Figure S4 shows that SRC mediates the phosphorylation of the C-terminal SHC1 at Y239/240, including molecular docking analysis of the EGFR-SHC1 and SRC interaction, along with immunoblotting validation in HEK-293T cells following SRC knockdown and in SYF cells reconstituted with wild-type or mutant SRC constructs.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Figure S4 shows that SRC mediates the phosphorylation of the C-terminal SHC1 at Y239/240, including molecular docking analysis of the EGFR-SHC1 and SRC interaction, along with immunoblotting validation in HEK-293T cells following SRC knockdown and in SYF cells reconstituted with wild-type or mutant SRC constructs.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Figure S2 shows that inactivation of the N-terminal EGFR kinase domain only partially abrogates the tumorigenicity of EGFR-SHC1, as demonstrated by soft agar colony formation assays. It also presents dose-response curves comparing the sensitivity of EGFR-RAD51 and EGFR-SHC1 to three EGFR-TKIs, along with immunoblotting analyses of downstream signaling inhibition following TKI treatment.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Figure S2 shows that inactivation of the N-terminal EGFR kinase domain only partially abrogates the tumorigenicity of EGFR-SHC1, as demonstrated by soft agar colony formation assays. It also presents dose-response curves comparing the sensitivity of EGFR-RAD51 and EGFR-SHC1 to three EGFR-TKIs, along with immunoblotting analyses of downstream signaling inhibition following TKI treatment.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Table S2 shows that individual clinicopathologic data have been reported in NSCLC patients with EGFR-fusions that were treated with EGFR-TKIs.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Table S2 shows that individual clinicopathologic data have been reported in NSCLC patients with EGFR-fusions that were treated with EGFR-TKIs.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Figure S1 shows the identification and validation of the EGFR-SHC1 fusion in NSCLC patients, including RT-PCR and Sanger sequencing confirmation, as well as the oncogenic potential of EGFR-SHC1 demonstrated through immunoblotting, flow cytometry, soft agar colony formation, and IL-3-independent proliferation assays in transfected Ba/F3 and NIH3T3 cells. It also presents structural modeling of EGFR-SHC1 binding to three EGFR-TKIs and the corresponding binding energy calculations.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Figure S1 shows the identification and validation of the EGFR-SHC1 fusion in NSCLC patients, including RT-PCR and Sanger sequencing confirmation, as well as the oncogenic potential of EGFR-SHC1 demonstrated through immunoblotting, flow cytometry, soft agar colony formation, and IL-3-independent proliferation assays in transfected Ba/F3 and NIH3T3 cells. It also presents structural modeling of EGFR-SHC1 binding to three EGFR-TKIs and the corresponding binding energy calculations.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Table S3 shows that oligonucleotides used in this study.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Table S3 shows that oligonucleotides used in this study.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Figure S5 shows that dual inhibition of afatinib plus SRC-TKIs represents a potential treatment strategy for EGFR-SHC1-driven tumors, including immunoblotting analyses of downstream signaling following combination treatment with afatinib and tirbanibulin, dose-response curves for the combination in Ba/F3-EGFR-SHC1 cells, and validation experiments using SRC knockdown or SHC1-inactivated mutants to confirm that the synergistic effects of dasatinib and afatinib are mediated through SRC-dependent SHC1 signaling.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer
Supplementary Figure S5 shows that dual inhibition of afatinib plus SRC-TKIs represents a potential treatment strategy for EGFR-SHC1-driven tumors, including immunoblotting analyses of downstream signaling following combination treatment with afatinib and tirbanibulin, dose-response curves for the combination in Ba/F3-EGFR-SHC1 cells, and validation experiments using SRC knockdown or SHC1-inactivated mutants to confirm that the synergistic effects of dasatinib and afatinib are mediated through SRC-dependent SHC1 signaling.